Research on factors predicting IVF outcomes in women with autoimmune diseases
Official title: Research of Predictive Factors of in Vitro Fertilization (IVF) Outcome in Women Affected by Autoimmune Disorders: From Biological Markers to Artificial Intelligence
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06872294 · Data updated 2026-11-12
This study is trying to find out what factors can help predict how well in vitro fertilization (IVF) works for women with autoimmune diseases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 43 Years |
| Sex | Women only |
| Enrollment | 200 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Pavia) |
| Status | Recruiting |
| Started | November 22, 2024 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | March 20, 2025 |
| Trial ID | NCT06872294 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women under 43 years old who are undergoing IVF with a fresh semen sample and have a sufficient count of progressive motile spermatozoa.
✕Probably not a fit
Patients with uterine abnormalities, chromosomal and genetic abnormalities, or positive serological tests for certain infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify predictive factors that influence the outcomes of in vitro fertilization (IVF) in women suffering from autoimmune diseases. It focuses on understanding how various biological and clinical factors, including the health status of the women and the quality of gametes, affect the success rates of IVF. The study utilizes artificial intelligence to enhance the prediction of successful pregnancies by analyzing data related to the patients' conditions and treatment responses. By examining these factors, the research seeks to improve IVF outcomes for women with specific health challenges.
Why it matters
Potential benefit: If successful, this study could lead to improved IVF success rates for women with autoimmune diseases.
How similar studies have gone: While there have been studies exploring IVF outcomes in relation to various factors, the specific use of AI in this context is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women with age below 43 years old * IVF cycle with fresh semen sample that could be used * progressive motile spermatozoa expected count of minimum 1 million following density gradient purification on the day of oocyte pick up Exclusion Criteria: * Women with uterine abnormalities * Women with chromosomal and genetic abnormalities * Positivity to serological test (HCV, HBV, HIV, VDRL-TPHA)
Where it's running
-
SSD Ostetricia e Ginecologia 2 - Fondazione IRCCS Policlinico San Matteo, Pavia
Pavia, Pavia, Italy Recruiting
Study contacts
- Principal investigator: Claudia Omes, PhD — Fondazione IRCCS Policlinico San Matteo di Pavia
- Study coordinator: Claudia Omes, PhD
- Email: c.omes@smatteo.pv.it
- Phone: +390382503238
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Music-4-MS: A 12-week music-based program to support thinking skills in people with MS
A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.